Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
•
Primary Care
Would you recommend patients with newly diagnosed bladder cancer to discontinue SGLT2 inhibitors?
Related Questions
In patients with localized small cell bladder cancer, would you consider consolidation with durvalumab after neoadjuvant chemotherapy followed by definitive local therapy (cystectomy or RT)?
How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
Do you plan to extrapolate from the NIAGARA trial regarding peri-operative durvalumab/cis/gem to treat upper tract urothelial carcinoma?
How do you manage dysgeusia from Enfortumab Vedotin?
For neoadjuvant treatment of muscle invasive bladder cancer, are you utilizing durvalumab plus gemcitabine cisplatin over dose dense or accelerated MVAC?
What is the optimal approach to systemic therapy for metastatic squamous cell carcinoma of the bladder considering the approval of enfortumab vedotin plus pembrolizumab for metastatic urothelial carcinoma?
How do you decide between internal versus external decompression of malignant obstruction of the ureter (MUO)?
Are you dose reducing/omitting IV dexamethasone as a pre-medication for anti-emesis in patients with MIBC when using durvalumab/gemcitabine/cisplatin?
How do you interpret NIAGARA efficacy given that adjuvant nivolumab was not administered in the comparator arm?
